Published in Eur J Nucl Med Mol Imaging on November 14, 2006
Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients. Eur J Nucl Med Mol Imaging (2013) 2.10
Initial clinical results for breath-hold CT-based processing of respiratory-gated PET acquisitions. Eur J Nucl Med Mol Imaging (2008) 1.59
Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors. J Nucl Med (2008) 1.40
Metabolic positron emission tomography imaging in cancer detection and therapy response. Semin Oncol (2011) 1.21
18F-FDG PET/CT imaging in oncology. Ann Saudi Med (2011) 1.08
Combined assessment of metabolic and volumetric changes for assessment of tumor response in patients with soft-tissue sarcomas. J Nucl Med (2008) 1.05
Assessment of histological response of paediatric bone sarcomas using FDG PET in comparison to morphological volume measurement and standardized MRI parameters. Eur J Nucl Med Mol Imaging (2010) 0.93
Modern diagnostic and therapeutic interventional radiology in lung cancer. J Thorac Dis (2013) 0.92
Respiratory motion handling is mandatory to accomplish the high-resolution PET destiny. Eur J Nucl Med Mol Imaging (2008) 0.92
Positron emission tomography/computerized tomography in lung cancer. Quant Imaging Med Surg (2014) 0.89
PET/CT for staging and monitoring non small cell lung cancer. Cancer Imaging (2008) 0.89
Potential of 18F-FDG PET toward personalized radiotherapy or chemoradiotherapy in lung cancer. Eur J Nucl Med Mol Imaging (2013) 0.88
Role of FDG-PET scans in staging, response assessment, and follow-up care for non-small cell lung cancer. Front Oncol (2013) 0.87
Positron emission tomography-computed tomography in the management of lung cancer: An update. South Asian J Cancer (2013) 0.86
Respiration-averaged CT for attenuation correction in non-small-cell lung cancer. Eur J Nucl Med Mol Imaging (2008) 0.82
Does early PET/CT assesment of response to chemotherapy predicts survival in patients with advanced stage non-small-cell lung cancer? Medicine (Baltimore) (2014) 0.81
Positron-emission tomography CT to identify local recurrence in stage I lung cancer patients 1 year after stereotactic body radiation therapy. Strahlenther Onkol (2013) 0.81
Prognostic Value of FDG-PET in patients with oropharyngeal carcinoma treated with concurrent chemoradiotherapy. Mol Imaging Biol (2008) 0.81
Neoadjuvant chemoradiotherapy or chemotherapy followed by surgery is superior to that followed by definitive chemoradiation or radiotherapy in stage IIIA (N2) nonsmall-cell lung cancer: a meta-analysis and system review. Onco Targets Ther (2016) 0.80
Interobserver and Intraobserver Variability among Measurements of FDG PET/CT Parameters in Pulmonary Tumors. Balkan Med J (2016) 0.75
The predictive value of (18)F-FDG PET-CT for assessing the clinical outcomes in locally advanced NSCLC patients after a new induction treatment: low-dose fractionated radiotherapy with concurrent chemotherapy. Radiat Oncol (2017) 0.75
Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med (2000) 6.34
Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg (1995) 3.31
SUV: standard uptake or silly useless value? J Nucl Med (1995) 2.96
Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol (2005) 2.22
Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res (2000) 2.13
Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol (1999) 1.95
Response evaluation criteria in solid tumors (RECIST): new guidelines. Med Pediatr Oncol (2001) 1.77
Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res (2006) 1.57
(18)F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J Nucl Med (2001) 1.54
FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. Lung Cancer (2002) 1.46
The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. J Nucl Med (1993) 1.35
18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med (2002) 1.33
Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. Ann Thorac Surg (2004) 1.30
The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer (1998) 1.27
The role of PET scan in diagnosis, staging, and management of non-small cell lung cancer. Oncologist (2004) 1.27
FDG PET measurement of the proliferative potential of non-small cell lung cancer. J Nucl Med (2000) 1.26
Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. Ann Thorac Surg (1999) 1.24
Grading of tumor regression in non-small cell lung cancer : morphology and prognosis. Chest (2001) 1.18
An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer. Ann Thorac Surg (2002) 1.14
Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer. Ann Thorac Surg (2004) 1.10
Characteristics of long-term survivors after treatment for inoperable carcinoma of the lung. Am J Clin Oncol (1985) 1.07
Is standardised (18)F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer? Eur J Nucl Med Mol Imaging (2005) 1.06
FDG PET in the evaluation of the aggressiveness of pulmonary adenocarcinoma: correlation with histopathological features. Nucl Med Commun (2000) 1.06
The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment. Lung Cancer (2003) 1.06
Determination of the prognostic value of [(18)F]fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer. Nucl Med Commun (2002) 1.03
Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma. J Thorac Cardiovasc Surg (2004) 1.03
Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer. Lancet (1994) 0.99
FDG PET for staging of advanced non-small cell lung cancer prior to neoadjuvant radio-chemotherapy. Eur J Nucl Med Mol Imaging (2002) 0.94
Whole-body 18FDG positron emission tomography in the staging of non-small cell lung cancer. Eur Respir J (1997) 0.93
Molecular whole-body cancer staging using positron emission tomography: consequences for therapeutic management and metabolic radiation treatment planning. Recent Results Cancer Res (2003) 0.83
Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol (2005) 5.19
Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol (2009) 4.38
Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data. Lancet Oncol (2009) 3.19
The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study. Lancet Neurol (2008) 2.42
PET/CT with 18F-FLT: does it improve the therapeutic management of metastatic germ cell tumors? J Nucl Med (2010) 2.22
Severe cutaneous reaction during radiation therapy with concurrent cetuximab. N Engl J Med (2007) 2.19
Survival prediction in terminally ill cancer patients by clinical estimates, laboratory tests, and self-rated anxiety and depression. J Clin Oncol (2007) 2.10
Retrospective evaluation of patients with uveal melanoma treated by stereotactic radiosurgery with and without tumor resection. JAMA Ophthalmol (2013) 1.99
Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients. J Clin Oncol (2008) 1.95
Impact of age on the relationships of brown adipose tissue with sex and adiposity in humans. Diabetes (2010) 1.90
Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med (2005) 1.81
The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma. J Urol (2008) 1.71
High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes. Radiother Oncol (2008) 1.65
The European Society of Thoracic Surgeons lung metastasectomy project. J Thorac Oncol (2010) 1.65
Pulmonary metastasectomy: a survey of current practice amongst members of the European Society of Thoracic Surgeons. J Thorac Oncol (2008) 1.58
Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer. BMC Cancer (2005) 1.57
The role of single-photon emission computed tomography/computed tomography in benign and malignant bone disease. Semin Nucl Med (2006) 1.56
Optimized contrast-enhanced CT protocols for diagnostic whole-body 18F-FDG PET/CT: technical aspects of single-phase versus multiphase CT imaging. J Nucl Med (2006) 1.55
Pneumonectomy: calculable or non-tolerable risk factor in trimodal therapy for Stage III non-small-cell lung cancer? Eur J Cardiothorac Surg (2012) 1.53
[Hemangiosarcoma after breast-conserving therapy of breast cancer: report of four cases with molecular genetic diagnosis and literature review]. Strahlenther Onkol (2011) 1.51
Hypoxia dose painting by numbers: a planning study. Int J Radiat Oncol Biol Phys (2007) 1.51
Dose-dependent attenuation of auditory phantom perception (tinnitus) by PET-guided repetitive transcranial magnetic stimulation. Hum Brain Mapp (2007) 1.50
Hybrid PET/MRI of intracranial masses: initial experiences and comparison to PET/CT. J Nucl Med (2010) 1.48
Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis (2008) 1.39
A kinetic model for dynamic [18F]-Fmiso PET data to analyse tumour hypoxia. Phys Med Biol (2005) 1.38
Primary pulmonary synovial sarcoma: a rare primary pulmonary tumor. Lung (2013) 1.32
Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. Eur J Cancer (2007) 1.30
Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients. Radiother Oncol (2006) 1.30
Correlation of stable elevations in striatal mu-opioid receptor availability in detoxified alcoholic patients with alcohol craving: a positron emission tomography study using carbon 11-labeled carfentanil. Arch Gen Psychiatry (2005) 1.29
Apoptosis-modulating agents in combination with radiotherapy-current status and outlook. Int J Radiat Oncol Biol Phys (2004) 1.27
Early changes in [18F]FLT uptake after chemotherapy: an experimental study. Eur J Nucl Med Mol Imaging (2002) 1.27
[11C]PIB binding in Parkinson's disease dementia. Neuroimage (2007) 1.24
DEGRO Practical Guidelines for palliative radiotherapy of breast cancer patients: brain metastases and leptomeningeal carcinomatosis. Strahlenther Onkol (2010) 1.21
Generation and transplantation of an autologous vascularized bioartificial human tissue. Transplantation (2009) 1.21
[18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group. J Clin Oncol (2008) 1.20
Bevacizumab as a treatment option for radiation-induced cerebral necrosis. Strahlenther Onkol (2011) 1.20
[18F]FLT PET for diagnosis and staging of thoracic tumours. Eur J Nucl Med Mol Imaging (2003) 1.18
Solitary pulmonary nodules: dynamic contrast-enhanced MR imaging--perfusion differences in malignant and benign lesions. Radiology (2004) 1.17
PET with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study. Eur J Nucl Med Mol Imaging (2004) 1.17
[68Ga]-DOTATOC-PET/CT for meningioma IMRT treatment planning. Radiat Oncol (2009) 1.16
Simultaneous whole-body PET/MR imaging in comparison to PET/CT in pediatric oncology: initial results. Radiology (2014) 1.15
Neurofibromatosis. Eur J Med Res (2009) 1.15
Hypofractionated reirradiation for recurrent malignant glioma. Strahlenther Onkol (2009) 1.13
Chest wall and intrathoracic desmoid tumors: surgical experience and review of the literature. Eur J Med Res (2009) 1.13
DEGRO practical guidelines for radiotherapy of breast cancer IV: radiotherapy following mastectomy for invasive breast cancer. Strahlenther Onkol (2014) 1.12
Systemic IgG4-related sclerosing disease: spectrum of imaging findings and differential diagnosis. AJR Am J Roentgenol (2012) 1.11
Alveolar inflammation in cystic fibrosis. J Cyst Fibros (2010) 1.11
DEGRO practice guidelines for palliative radiotherapy of metastatic breast cancer: bone metastases and metastatic spinal cord compression (MSCC). Strahlenther Onkol (2009) 1.10
Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer: mature results of a phase II trial. Strahlenther Onkol (2008) 1.09
Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis. BMC Cancer (2005) 1.08
Treatment of lung cancer in the elderly. Part I: non-small cell lung cancer. Lung Cancer (2003) 1.08
Multicenter comparison of calibration and cross calibration of PET scanners. J Nucl Med (2002) 1.07
Distribution of prostate sentinel nodes: a SPECT-derived anatomic atlas. Int J Radiat Oncol Biol Phys (2010) 1.07
Intraoperative radiotherapy as accelerated partial breast irradiation for early breast cancer : beware of one-stop shops? Strahlenther Onkol (2010) 1.06
DEGRO practical guidelines for radiotherapy of breast cancer I: breast-conserving therapy. Strahlenther Onkol (2007) 1.05
Added value of SPECT/CT in patients suspected of having bone infection: preliminary results. Arch Orthop Trauma Surg (2006) 1.04
Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET. Eur J Nucl Med Mol Imaging (2002) 1.03
Dopamine transporter positron emission tomography in spinocerebellar ataxias type 1, 2, 3, and 6. Arch Neurol (2005) 1.02
Rational diagnosis of squamous cell carcinoma of the head and neck region: comparative evaluation of CT, MRI, and 18FDG PET. AJR Am J Roentgenol (2005) 1.02
Hypoxia-imaging with (18)F-Misonidazole and PET: changes of kinetics during radiotherapy of head-and-neck cancer. Radiother Oncol (2007) 1.02
Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol Cancer (2010) 1.01
Current and future strategies in radiotherapy of childhood low-grade glioma of the brain. Part II: Treatment-related late toxicity. Strahlenther Onkol (2003) 1.01
A model of reoxygenation dynamics of head-and-neck tumors based on serial 18F-fluoromisonidazole positron emission tomography investigations. Int J Radiat Oncol Biol Phys (2007) 0.99
Decreased 3D observer variation with matched CT-MRI, for target delineation in Nasopharynx cancer. Radiat Oncol (2010) 0.99
DEGRO practical guidelines for radiotherapy of breast cancer II. Postmastectomy radiotherapy, irradiation of regional lymphatics, and treatment of locally advanced disease. Strahlenther Onkol (2008) 0.99
Low dose non-enhanced CT versus standard dose contrast-enhanced CT in combined PET/CT protocols for staging and therapy planning in non-small cell lung cancer. Eur J Nucl Med Mol Imaging (2006) 0.98
Radiotherapy and "new" drugs-new side effects? Radiat Oncol (2011) 0.98
Highly variable response to cytotoxic chemotherapy in carcinoma-associated fibroblasts (CAFs) from lung and breast. BMC Cancer (2008) 0.98
Corticomedullary differentiation and maturational arrest in thymomas. Histopathology (2013) 0.97
Improved detection of splenosis in patients with haematological disorders: the role of combined transmission-emission tomography. Eur J Nucl Med Mol Imaging (2002) 0.97
Accuracy of parathyroid imaging: a comparison of planar scintigraphy, SPECT, SPECT-CT, and C-11 methionine PET for the detection of parathyroid adenomas and glandular hyperplasia. Diagn Interv Radiol (2011) 0.97
Benefit of anatomical-functional image fusion in the diagnostic work-up of neuroendocrine neoplasms. Eur J Nucl Med Mol Imaging (2003) 0.97
Intensity modulated radiotherapy for high risk prostate cancer based on sentinel node SPECT imaging for target volume definition. BMC Cancer (2005) 0.96
Radiation therapy in the multimodal treatment approach of pituitary adenoma. Strahlenther Onkol (2002) 0.96
Marginal zone B-cell non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue type: imaging findings. AJR Am J Roentgenol (2008) 0.95
Surgery on unfavourable persistent N2/N3 non-small-cell lung cancer after trimodal therapy: do the results justify the risk? Interact Cardiovasc Thorac Surg (2012) 0.95
Serotonergic dysfunction: brain imaging and behavioral correlates. Cogn Affect Behav Neurosci (2006) 0.95
Stereotactic fractionated radiotherapy in patients with optic nerve sheath meningioma. Int J Radiat Oncol Biol Phys (2002) 0.95
Radiologic spectrum of extramedullary relapse of myelogenous leukemia in adults. AJR Am J Roentgenol (2007) 0.94
External beam radiotherapy as postoperative treatment of diffuse pigmented villonodular synovitis. Int J Radiat Oncol Biol Phys (2006) 0.94
Induction chemotherapy with paclitaxel and cisplatin followed by radiotherapy for larynx organ preservation in advanced laryngeal and hypopharyngeal cancer offers moderate late toxicity outcome (DeLOS-I-trial). Eur Arch Otorhinolaryngol (2008) 0.94
Sequential expression of adhesion and costimulatory molecules in graft-versus-host disease target organs after murine bone marrow transplantation across minor histocompatibility antigen barriers. Biol Blood Marrow Transplant (2005) 0.93